PEDIATRIC ONCOLOGY STUDY GROUP

临床和实验室研究活动正在进行， 儿科肿瘤学研究组（POG）。 我们 参与合作性癌症治疗试验， 手术和/或放射疗法和/或化学疗法的组合 白血病、淋巴瘤和各种癌症的临床研究 儿童实体瘤 这些试验的当前结果总结如下 在某些情况下已经出版，并汇编了有关的 这些合作小组的出版物可从 儿科肿瘤组办公室。 我们还参加了几个 新药治疗方案的试点研究和II期试验。 的 伯明翰的亚拉巴马大学（UAB）目前正在提供参考 对所有新感染者进行免疫学评价实验室支持 儿童淋巴细胞白血病患者。 我们进行前B细胞 分析，以确定一组以前的免疫表型， 未分类的非B非T白血病 此外，T细胞免疫 对所有可用的POG患者进行子集评估， 使用单克隆抗体的玫瑰花结阳性白血病或淋巴瘤 针对T细胞分化抗原。 这些研究应 允许更好地表征和分类淋巴恶性肿瘤 在童年。 UAB研究人员还提供了一个免疫遗传学参考 实验室评估黑人患者的HLA和DR表型， 淋巴细胞白血病和一组白色患者， 神经母细胞瘤 对所有新病人的材料进行BF分型 与所有。 我们正在研究这种分型预测风险的能力， 或抵抗恶性肿瘤。 我们还在寻找 一旦确定恶性肿瘤，特异性表型对生存的影响。 第三 POG参考实验室检查了循环免疫 神经母细胞瘤、淋巴母细胞白血病和骨肉瘤中的复合物， 与疾病活动的相关性。 最后，POG血清/血浆库 已在UAB建立，用于保存从 所有恶性疾病患者用于研究目的。

Clinical and laboratory investigative activities are being performed in collaboration with the Pediatric Oncology Study Group (POG). We are participating in cooperative cancer therapy trials which utilize a combination of surgery and/or radiation therapy and/or chemotherapy for the investigative clinical trials of leukemias, lymphomas, and a variety of childhood solid tumors. Summaries of current results of these trials are in some cases already published, and a compilation of pertinent publications from these cooperative group efforts can be obtained from the Pediatric Oncology Group office. We are also participating in several pilot studies of new drug treatment programs and Phase II trials. The University of Alabama in Birmingham (UAB) is currently providing reference laboratory support for performing immunologic evaluation of all new pediatric patients with lymphoblastic leukemia. We perform pre-B cell analysis to determine the immunologic phenotype of a group of formerly unclassified non-B, non-T leukemias. Additionally, T-cell immunologic subset evaluations are performed on all available POG patients with E rosette positive leukemias or lymphomas using monoclonal antibodies directed against T-cell differentiation antigens. These studies should allow better characterization and classification of lymphoid malignancies in childhood. UAB investigators also provide an immunogenetics reference laboratory to evaluate HLA and DR phenotypes on black patients with lymphoblastic leukemia and on a group of white patients with neuroblastoma. Bf typing is perofrmed on material from all new patients with ALL. We are examining the ability of this typing to predict risk for, or resistance to, malignancy. We are also looking for relationships of specific phenotypes to survival once malignancy is established. A third POG reference laboratory examines the incidence of circulating immune complexes in neuroblastoma, lymphoblastic leukemia, and osteosarcoma and their correlation with disease activity. Finally, a POG serum/plasma bank has been established at UAB for maintaining frozen material obtained from all patients with malignant diseases for research purposes.